Is Edwards Lifesciences Stock Outperforming the S&P 500?

NodeGuardian

2026-03-20 20:02:57

Abstract generation in progress

Edwards Lifesciences (EW) has recently outperformed the S&P 500 over the past three months and 52 weeks, despite a YTD decline. The company, focused on cardiovascular medical devices, recently divested its critical care unit to prioritize high-growth areas. Analysts maintain a “Moderate Buy” rating for EW, projecting a 15.9% upside from current price levels.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes